Osteoporosis International

, Volume 23, Issue 12, pp 2873–2884

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases

  • M. Pazianas
  • B. Abrahamsen
  • Y. Wang
  • R. G. G. Russell
Original Article



In a cohort study of users of bisphosphonates, we evaluated the incidence of fragility fractures at all sites on the femur following for up to 8 years of therapy with alendronate or risedronate. We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates.


Few studies have acquired adequate data with prolonged follow-up on bisphosphonate users in the general population to evaluate their long-term effects on the risk of hip fractures including those in the subtrochanteric region.


This cohort study utilizes a large USA database (January 1, 2000 to June 30, 2009). We compared patients with higher versus lower degrees of compliance [medication possession ratio, MPR <1/3 (the reference), 1/3–<2/3, or ≥2/3]. Radiographic adjudication of fracture site and features were not performed. Hazard ratios (HR) for fracture were estimated using time-dependent Cox models. Restricted cubic splines (RCS) were used to plot HRs for fracture against duration of therapy.


There were 3,655 incident cases of femoral fracture (764 subtrochanteric/shaft, 2,769 hip) identified during 917,741 person-years of follow-up (median = 3 years) on 287,099 patients (267,374 were women) from the date when they initiated oral bisphosphonate therapy. The corresponding HRs (95% confidence interval, CI) for overall femoral fractures associated with each additional year of therapy were 0.93 (0.86–1.01) within 5 years, and 0.89 (0.77–1.03) beyond 5 years for risedronate and 0.86 (0.81–0.91) and 0.95 (0.84–1.07) for alendronate, respectively. The corresponding estimates for subtrochanteric/shaft fractures were 1.05 (0.87–1.26) and 0.89 (0.60–1.33) for risedronate and 0.99 (0.92–1.05) and 1.05 (0.92–1.20) for alendronate, respectively. The HRs (95% CI) for overall femoral fractures associated with each additional year of alendronate or risedronate therapy within 5 and beyond 5 years were not significantly different.


Our study showed persistence of overall hip fracture protection with long-term use of alendronate or risedronate.


Atypical femur fractures Femoral shaft fractures Fragility fractures Low-energy femoral fractures Medication possession ratio Oral bisphosphonates Subtrochanteric fractures 

Supplementary material

198_2012_1952_MOESM1_ESM.doc (320 kb)
Appendix 1Baseline variables that were considered but did not make any appreciable difference in results included nutrient deficiency, diseases of the digestive system, genitourinary diseases, muskuloskeletal disorders, knee or hip surgeries, COPD, other respiratory diseases, disorders in the artery or vein systems, cerebral vascular disorders, other heart disease, pulmonary diseases, circulatory and ischemic heart disease separately, HBP, Parkinson’s, alcoholism, smoking, dementia, blood system disease, use of ACE inhibitors, anti-arrhythmic drugs, antibiotics, anticoagulants, ARBs, beta-blockers, BDZs, calcitonin, calcium channel blockers, anticonvulsants, digitalis, diuretics, hypoglycemics, NSAIDS, PPIs, psychotherapy, raloxifene, SSRIs, STATINS, and thyroxin. (DOC 319 kb)


  1. 1.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321Google Scholar
  2. 2.
    Pazianas M, Cooper C, Ebetino FH, Russell RG (2010) Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 21(6):325–43Google Scholar
  3. 3.
    Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 26(3):553–60. doi:10.1002/jbmr.233 PubMedCrossRefGoogle Scholar
  4. 4.
    Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783–9PubMedCrossRefGoogle Scholar
  5. 5.
    Pazianas M, Abrahamsen B (2011) Safety of bisphosphonates. Bone 49(1):103–10, Epub 2011 Jan 12. PubMed PMID: 21236370PubMedCrossRefGoogle Scholar
  6. 6.
    Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294. doi:10.1002/jbmr.253 PubMedCrossRefGoogle Scholar
  7. 7.
    Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22(2):373–90, Epub 2010 Nov 18PubMedCrossRefGoogle Scholar
  8. 8.
    Adamson DM, Chang S, Hansen LG (2008) Health research data for the real world: the Marketscan databases. Thompson Healthcare, New YorkGoogle Scholar
  9. 9.
    Dobson AJ, Kuulasmaa K, Eberle E, Scherer J (1991) Confidence intervals for weighted sums of Poisson parameters. Stat Med 10(3):457–62PubMedCrossRefGoogle Scholar
  10. 10.
    Fisher LD, Lin DY (1999) Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20:145–57PubMedCrossRefGoogle Scholar
  11. 11.
    Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565–74, discussion 575–7PubMedCrossRefGoogle Scholar
  12. 12.
    Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W (2006) The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 22(7):1249–56PubMedCrossRefGoogle Scholar
  13. 13.
    Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E (2008) Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 23(9):1435–41Google Scholar
  14. 14.
    Heinzl H, Kaider A (1997) Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comput Methods Programs Biomed 54(3):201–8PubMedCrossRefGoogle Scholar
  15. 15.
    Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8(5):551–61PubMedCrossRefGoogle Scholar
  16. 16.
    Heinzl H, Kaider A, Zlabinger G (1996) Assessing interactions of binary time-dependent covariates with time in Cox proportional hazards regression models using cubic spline functions. Stat Med 15:25899–2601CrossRefGoogle Scholar
  17. 17.
    Abrahamsen B, Eiken P, Eastell R (2010) Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 95(12):5258–65, Epub 2010 Sep 15Google Scholar
  18. 18.
    Lefebvre G, Angers JF, Blais L (2006) Estimation of time-dependent rate ratios in case–control studies: comparison of two approaches for exposure assessment. Pharmacoepidemiol Drug Saf 15(5):304–16PubMedCrossRefGoogle Scholar
  19. 19.
    Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH (2011) Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res 26(5):993–1001. doi:10.1002/jbmr.288 PubMedCrossRefGoogle Scholar
  20. 20.
    Salminen ST, Pihlajamäki HK, Avikainen VJ, Böstman OM (2000) Population based epidemiologic and morphologic study of femoral shaft fractures. Clin Orthop Relat Res 372:241–9PubMedCrossRefGoogle Scholar
  21. 21.
    Salminen ST. Femoral shaft fractures in adults: epidemiology, fracture patterns, nonunions, and fatigue fractures. Helsinki University Printing House, Helsinki 2005 ISBN 952-10-2523-9, http://www.doria.fi/bitstream/handle/10024/2183/femorals.pdf?sequence=1
  22. 22.
    Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20(8):1353–62, Epub 2008 Dec 9PubMedCrossRefGoogle Scholar
  23. 23.
    Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728–37PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • M. Pazianas
    • 1
    • 6
  • B. Abrahamsen
    • 2
    • 3
  • Y. Wang
    • 4
  • R. G. G. Russell
    • 1
    • 5
  1. 1.The Botnar Research CentreOxford UniversityOxfordUK
  2. 2.Department of Medicine FGentofte HospitalCopenhagenDenmark
  3. 3.OPEN, Institute of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
  4. 4.P&G Pharmaceuticals, Epidemiology & Health OutcomesMasonUSA
  5. 5.The Mellanby Centre for Bone ResearchSheffield UniversitySheffieldUK
  6. 6.Oxford University Institute of Musculoskeletal Sciences, the Botnar Research Centre and Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal DiseasesOxford UniversityOxfordUK

Personalised recommendations